| HER3 signaling and targeted therapy in cancer R Mishra, H Patel, S Alanazi, L Yuan, JT Garrett Oncology reviews 12 (1), 2018 | 220 | 2018 |
| PI3K inhibitors in cancer: clinical implications and adverse effects R Mishra, H Patel, S Alanazi, MK Kilroy, JT Garrett International journal of molecular sciences 22 (7), 3464, 2021 | 200 | 2021 |
| Current advances in the treatment of BRAF-mutant melanoma H Patel, N Yacoub, R Mishra, A White, L Yuan, S Alanazi, JT Garrett Cancers 12 (2), 482, 2020 | 165 | 2020 |
| Activating HER3 mutations in breast cancer R Mishra, S Alanazi, L Yuan, T Solomon, TM Thaker, N Jura, JT Garrett Oncotarget 9 (45), 27773, 2018 | 33 | 2018 |
| BRAF mutant melanoma adjusts to BRAF/MEK inhibitors via dependence on increased antioxidant SOD2 and increased reactive oxygen species levels L Yuan, R Mishra, H Patel, S Alanazi, X Wei, Z Ma, JT Garrett Cancers 12 (6), 1661, 2020 | 31 | 2020 |
| IGF1R/IR mediates resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma H Patel, R Mishra, N Yacoub, S Alanazi, MK Kilroy, JT Garrett Cancers 13 (22), 5863, 2021 | 21 | 2021 |
| Phosphoinositide 3-Kinase (PI3K) reactive oxygen species (ROS)-activated prodrug in combination with anthracycline impairs pi3k signaling, increases DNA damage response and … R Mishra, L Yuan, H Patel, AS Karve, H Zhu, A White, S Alanazi, P Desai, ... International Journal of Molecular Sciences 22 (4), 2088, 2021 | 20 | 2021 |
| HER3 alterations in cancer and potential clinical implications MK Kilroy, SY Park, W Feroz, H Patel, R Mishra, S Alanazi, JT Garrett Cancers 14 (24), 6174, 2022 | 9 | 2022 |
| HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018; 12 (1): 355 R Mishra, H Patel, S Alanazi, L Yuan, JT Garrett Epub 2018/07/31. https://doi. org/10.4081/oncol. 2018.355 PMID: 30057690, 0 | 6 | |
| HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers SM Alanazi, W Feroz, R Mishra, MK Kilroy, H Patel, L Yuan, SJ Storr, ... Plos one 18 (5), e0285251, 2023 | 5 | 2023 |
| Role of HER3 signaling pathways in ER+ and HER2+ breast cancers R Mishra, S Alanazi, H Patel, L Yuan, JT Garrett Cancer Research 79 (13_Supplement), 389-389, 2019 | 2 | 2019 |
| IGF1R/IR mediates resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma. Cancers. 2021; 13: 5863 H Patel, R Mishra, N Yacoub, S Alanazi, MK Kilroy, JT Garrett s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| role of her3 v104l mutation on tumor growth and her3 stabilization R Mishra, MK Kilroy, W Feroz, H Patel, S Alanazi, JT Garrett Cancer Research 83 (7_Supplement), 3916-3916, 2023 | | 2023 |
| The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance MK Kilroy, R Mishra, A Stupecki, W Feroz, S Alanazi, JT Garrett Cancer Research 83 (7_Supplement), 3988-3988, 2023 | | 2023 |
| The role of non-muscle myosin IIa in HER2+ breast cancer tumorigenesis S Alanazi University of Cincinnati, 2023 | | 2023 |
| Role of her3 mutations on breast cancer oncogenesis R Mishra, MK Kilroy, H Patel, S Alanazi, JT Garrett Cancer Research 82 (12_Supplement), 5412-5412, 2022 | | 2022 |
| Abstract P5-10-05: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers SM Alanazi, R Mishra, H Patel, L Yuan, MK Kilroy, JT Garrett Cancer Research 82 (4_Supplement), P5-10-05-P5-10-05, 2022 | | 2022 |
| HER3 Alterations in Cancer and Potential Clinical Implications. Cancers 2022, 14, 6174 MK Kilroy, S Park, W Feroz, H Patel, R Mishra, S Alanazi, JT Garrett s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| The role of non-muscle myosin IIA in HER2+ breast cancers SM Alanazi, R Mishra, L Yuan, H Patel, J Garrett Cancer Research 80 (16_Supplement), 4205-4205, 2020 | | 2020 |
| Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma H Patel, R Mishra, N Broit, N Yacoub, L Yuan, S Alanazi, N Hayward, ... Cancer Research 80 (16_Supplement), 1894-1894, 2020 | | 2020 |
Rosalin MishraResearch Associate, University of Cincinnati在 ucmail.uc.edu 的电子邮件经过验证
Rosalin MishraResearch Associate, University of Cincinnati在 ucmail.uc.edu 的电子邮件经过验证